导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.72% | 1984/4773 |
| 近一周 | -2.29% | 2771/5458 |
| 近一月 | -4.13% | 2650/5421 |
| 近一季 | -0.74% | 1226/5205 |
| 近半年 | -4.96% | 2863/4920 |
| 近一年 | 6.20% | 1597/4361 |
| 近两年 | 67.25% | 1050/2954 |
| 近三年 | 40.89% | 717/2253 |
| 成立以来 | 75.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.08% 1641/4961 |
8.12% 2624/5312 |
- - |
- - |
| 2025 | 29.50% 1394/4813 |
4.32% 958/3635 |
2.42% 1576/4076 |
19.88% 2084/4524 |
1.10% 1537/4813 |
| 2024 | 11.40% 1325/3463 |
0.48% 966/2808 |
-3.24% 1327/3014 |
14.33% 2003/3129 |
0.22% 1248/3463 |
| 2023 | -2.64% 597/2656 |
9.37% 408/2280 |
-2.57% 611/2385 |
-4.48% 1153/2515 |
-4.34% 971/2655 |
| 2022 | -9.77% 187/2207 |
-8.57% 286/1919 |
5.73% 839/2016 |
-9.05% 241/2113 |
2.62% 881/2208 |
| 2021 | 27.38% 90/1822 |
1.54% 251/1255 |
12.31% 339/1330 |
7.70% 174/1466 |
3.71% 399/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 招商中证500等权重指数增强C VS. 长安沪深300非周期A(740101) |